Skip to main content
. Author manuscript; available in PMC: 2023 Aug 10.
Published in final edited form as: Nat Microbiol. 2020 Feb 3;5(3):473–485. doi: 10.1038/s41564-019-0651-y

Figure 4. Optimising multiprotein vaccines to minimise IPD.

Figure 4

a-b, These plots summarise the protein-based formulations identified when optimising to minimise infant, overall or AMR IPD (as indicated by the first column). These were composed of a mixture of immunogenic proteins found at intermediate frequencies (5%-95%) in the pneumococcal populations of a, Massachusetts (12 proteins) and b, Maela (10 proteins), respectively (n = 20 formulations for each combination of optimisation constraint and criterion in each population). Results are otherwise displayed as described for Figure 2c-d, with rows ordered by the formulations’ effectiveness in minimising infant IPD. c-d, These plots summarise combined vaccination strategies in which a capsule-based CAV was devised for each multiprotein infant vaccine. Results are displayed as described in Figure 3c-d.